EUVIMEDEUVIMED entdecken
CrossrefInfokarte

HDAC3 drives type II alveolar epithelial barrier dysfunction via MKP1 deacetylation in radiation‐induced lung injury

Boyang Li, Ning Li, Rui Xiong, Yifan Zuo, Yi Liu, Guoqing Luo, Wenjun Zhang, Zhuya Xiao, Long Wu, Min Peng

Clinical and Translational Medicine · 2026-11 · 16 (11)

DOI: 10.1002/ctm2.70877 ↗
AbstractBibliografische Angaben

Abstract

Abstract Histone deacetylase 3 (HDAC3) is a key biological macromolecule involved in protein acetylation and inflammatory signalling. Although its biological functions are well recognised, the molecular mechanisms through which HDAC3 regulates stress‐induced responses of alveolar epithelial cells during early‐stage radiation‐induced lung injury (RILI) remain incompletely understood. In this study, using AT2‐specific HDAC3 conditional knockout mice as well as primary mouse AT2 and A549 cell models, we found that radiation markedly upregulates HDAC3 expression, whereas HDAC3 knockdown alleviates radiation‐induced disruption of the alveolar epithelial barrier. Transcriptomic analysis further revealed that HDAC3 influences barrier integrity by modulating MAPK‐mediated inflammation and apoptosis. Pharmacological intervention with the selective HDAC3 inhibitor RGFP966 also demonstrated that HDAC3 inhibition mitigates radiation‐induced oxidative stress imbalance. Mechanistically, HDAC3 deacetylates MKP1, enhancing p38 mitogen‐activated protein kinase (p38 MAPK) phosphorylation, promoting FBJ murine osteosarcoma viral oncogene homolog (c‐Fos) expression, and activating activator protein‐1 (AP‐1), thereby driving downstream inflammatory signalling. Collectively, our findings support a role for the HDAC3–MKP1–p38 MAPK–c‐Fos/AP‐1 axis in regulating inflammatory responses in AT2 cells and highlight HDAC3 as a potential molecular target for mitigating alveolar epithelial injury in early‐stage RILI.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →